For example, you can get $570 off the price of a one-month supply of 0.25 mg or 0.5 mg doses, saving you nearly $7,000 per year
We know everyone's different, so your treatment matches your needs
1 options Product Code
Competitive Landscape GLP-1 Weight Loss Drug Market Competitive Landscape: Novo Nordisk and Eli Lilly Duopoly, Oral GLP-1 Challengers, and Telehealth Platforms Reshape the Obesity Drug Market Through 2035 The GLP-1 Weight Loss Drug Market competitive landscape is defined by exceptional concentration at the approved drug tier where Novo Nordisk and Eli Lilly collectively control approximately 87% of global prescription obesity drug revenue combined with intense clinical development competition among more than 40 active GLP-1 pipeline programs
For example, Novo Nordisk, the manufacturer of Ozempic, offers a patient assistance program for uninsured or Medicare patients who qualify and are prescribed Ozempic for type 2 diabetes
Most feel more in control, less stressed, and more optimistic about their well-being